Trial Profile
A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization with Burkholderia spp.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs OligoG (Primary)
- Indications Burkholderia infections; Cystic fibrosis
- Focus Pharmacodynamics
- Sponsors AlgiPharma
- 18 Apr 2018 Status changed from active, no longer recruiting to completed.
- 26 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 May 2017.
- 26 Jan 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.